Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 0.61 |
| ▸ | EYA3 | Q99504 | 4/20 | 0.57 |
| ▸ | THRA | P10827 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490125 | 0.86 | EYA3 (0.69) | CYP2C19EYA3THRATHRBCYP2C9 | |
| SCHEMBL6482824 | 0.85 | THRA (0.72) | CYP2C19EYA3THRATHRBCYP2C9 | |
| SCHEMBL27586552 | 0.82 | CYP2C19 (0.64) | CYP2C19EYA3THRATHRBCYP2C9 | |
| SCHEMBL8994709 | 0.76 | CYP2C19 (1.00) | CYP2C19EYA3CYP2C9KDM7AL3MBTL1 | |
| SCHEMBL28245008 | 0.75 | CYP2C19 (0.79) | CYP2C19EYA3THRATHRBCYP2C9 | |
| SCHEMBL18018241 | 0.73 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9POLBGAA | |
| SCHEMBL3219908 | 0.73 | EYA3 (1.00) | CYP2C19EYA3THRATHRBCYP2C9 | |
| SCHEMBL6731441 | 0.73 | GLRA1 (0.43) | CYP2C19CYP2C9POLBGAA | |
| SCHEMBL28245012 | 0.72 | CYP2C19 (0.79) | CYP2C19EYA3THRATHRBCYP2C9 | |
| SCHEMBL8994710 | 0.71 | CYP2C19 (1.00) | CYP2C19EYA3THRATHRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065208-A1 | Benzofuranes and their use in the treatment of atrial fibrillation | KARO BIO AB (SE) | 2005-03-24 | — | — | US | disclosed |
| CN-1533274-A | Benzofuranes and their use in treatment of artrial fibrillation | �����ɷ� | 2004-09-29 | — | — | CN | disclosed |
| EP-1408958-A1 | BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION | KARO BIO AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003009839-A1 | BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION | KARO BIO AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065208-A1 | Benzofuranes and their use in the treatment of atrial fibrillation | KCNH1, KCNJ2, KCNQ2 | CYP2C19 240/4885EYA3 3572/4885THRA 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.